A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

Inclusion Criteria: * Written informed consent/assent * General good health * Asthma or COPD * Capable of understanding the requirements, risks, and benefits of study participation. * Able to demonstrate proper metered-dose inhaler use and technique. * Other inclusion criteria apply Exclusion Criteria: * History of life-threatening asthma or COPD that is defined for this protocol as an asthma or COPD episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures. * Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks of Screening Visit. * Is being treated with a long-acting β2-agonist alone. * Is currently being treated with Ventolin HFA. * Any asthma or COPD exacerbation requiring oral corticosteroids within 2 months of Screening Visit. A subject must not have had any hospitalization for asthma or COPD within 4 months prior to Screening Visit. * Historical or current evidence of a clinically significant non-asthmatic acute or chronic condition. * Uncontrolled hypertension * History of any adverse reaction to any component of the HFA-MDI formulation. * Participation in any investigational drug study within the 30 days preceding the Screening Visit. * Other exclusion criteria apply.